Precision autoimmune cell therapy is expected to become a new method of liver cancer treatment

Precision autoimmune cell therapy is expected to become a new method of liver cancer treatment

Precision autoimmune cell therapy is expected to become a new method for the treatment of liver cancer Precision autoimmune cell therapy is expected to become a new method for the treatment of liver cancer

The team of Huang Zhiyong, professor of Hepatobiliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and the team of professor Xia Tian from the School of Artificial Intelligence and Automation , carried out clinical trials of autologous tumor infiltrating lymphocyte (TIL) therapy technology in advanced liver cancer.
The results were recently published online in " Journal of Clinical Surgery
.

Huang Zhiyong's team and the summer team of the School of Artificial Intelligence and Automation have carried out clinical trials of autologous tumor infiltrating lymphocyte (TIL) therapy technology in advanced liver cancer.
The results were recently published online in the "Journal of Clinical Surgery"
.

TIL is a kind of adoptive cell therapy.
It was pioneered by Steven Rosenberg, a professor at the National Cancer Institute, at the end of the last century.
However, this method is complicated to implement, has many links , has a long cycle, and has a low success rate, making it difficult for large-scale clinical application
.

, The cycle is long, and the success rate is not high, it is still difficult to large-scale clinical promotion
.

In 2019, Huang Zhiyong worked with the Xia Tian team to design a clinical trial of smart TIL cell therapy combined with immune node inhibitor therapy, and the clinical trial was carried out with the support of Tongji Medical College of Huazhong University of Science and Technology and Tongji Hospital
.

Huang Zhiyong worked with the Xia Tian team to design a clinical trial of smart TIL cell therapy combined with immune node inhibitor therapy.
The clinical trial was carried out with the support of Tongji Medical College of Huazhong University of Science and Technology and Tongji Hospital
.

The research team used artificial intelligence and information engineering technology to innovate the traditional TIL therapy technology, accurately screened the tumor-specific lymphocytes, and efficiently expanded their numbers in vitro, and returned them to the patient's body, and observed good safety and effectiveness
.

Among them, one patient with bilateral adrenal metastasis after hepatocellular carcinoma was treated with TIL reinfusion combined with PD-1 monoclonal antibody for 12 weeks and found that the right adrenal metastasis was partially necrotic, and alpha-fetoprotein decreased significantly, reaching a partial response (PR).
)
.

Another patient with liver cancer with scattered metastases in both lungs was given TIL reinfusion therapy combined with PD-1 monoclonal antibody treatment for 11 weeks and found that the metastases in both lungs disappeared and reached a complete response (CR)

The research is an exploration of combined immunotherapy, and the therapeutic effect has been verified in clinical trials
.

Studies have shown that the infusion of TIL after in vitro amplification and anti-PD-1 monoclonal antibody is safe and feasible to treat patients with advanced liver cancer.

Related paper information: https://doi.

https://doi.
org/ 10.
3969/j.
issn.
1005-6483.
2021.
08.
014 10.
3969/j.
issn.
1005-6483.
2021.
08.
014